Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists

J Diabetes. 2014 Mar;6(2):164-6. doi: 10.1111/1753-0407.12077. Epub 2013 Dec 6.
No abstract available

Keywords: dipeptidyl peptidase-4 inhibitors; glucagon-like peptide-1 receptor agonists; tailored therapy.

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Glucose / metabolism*
  • Carbamates / therapeutic use
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
  • Drug Therapy, Combination
  • Exenatide
  • Fasting / blood
  • Female
  • Glucagon-Like Peptide-1 Receptor
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Insulin Glargine
  • Insulin, Long-Acting / therapeutic use
  • Metformin / therapeutic use
  • Middle Aged
  • Peptides / metabolism
  • Peptides / therapeutic use
  • Piperidines / therapeutic use
  • Pyrazines / therapeutic use*
  • Receptors, Glucagon / agonists
  • Receptors, Glucagon / metabolism
  • Sitagliptin Phosphate
  • Treatment Failure
  • Triazoles / therapeutic use*
  • Venoms / metabolism
  • Venoms / therapeutic use

Substances

  • Blood Glucose
  • Carbamates
  • Dipeptidyl-Peptidase IV Inhibitors
  • GLP1R protein, human
  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Insulin, Long-Acting
  • Peptides
  • Piperidines
  • Pyrazines
  • Receptors, Glucagon
  • Triazoles
  • Venoms
  • Insulin Glargine
  • repaglinide
  • Metformin
  • Exenatide
  • Sitagliptin Phosphate